Broken redirects

The following redirects link to non-existent pages:

Showing below up to 50 results in range #821 to #870.

821. EAFT → European Atrial Fibrillation Trial
822. ECST → European Carotid Surgery Trial
823. EUROSTAR → European Cobalt Stent With Antiproliferative For Restenosis Trial
824. ECASS III → European Cooperative Acute Stroke Study III
825. ECSG-1 → European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator
826. ECSG-6 → European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator II
827. ECSS → European Coronary Surgery Study Group
828. ELUTES → European Evaluation Of Paclitaxel Eluting Stent
829. EMIT → European Mivazerol Trial
830. EMIAT → European Myocardial Infarction Amiodarone Trial
831. EMIP-FR → European Myocardial Infarction Project—Free Radicals
832. E-SIRIUS → European Sirolimus-Eluting Stent In Coronary Lesions
833. ESHRE → European Society of Human Reproduction and Embryology
834. EURO-SPAH → European Sonotherapy Trial To Prevent Arterial Hyperplasia
835. ESPS2 → European Stroke Prevention Study 2
836. ESPS-2 → European Stroke Prevention Study 2
837. ESTAT → European Stroke Treatment With Ancrod Trial
838. EUTOPIA → European Trial On Olmesartan And Pravastatin In Inflammation And Atherosclerosis
839. EUROPA → European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease
840. ELECT → Evaluating Enoxaparin (Lovenox) Clotting Times
841. EPIC → Evaluation Of C7E3 For The Prevention Of Ischemic Complications
842. EDGE → Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities
843. EDGECAP → Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Community-Acquired Pneumonia
844. EDGESST → Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Skin And Soft Tissue Infections
845. EDGEUTI → Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Urinary Tract Infection
846. A to Z, Phase Z → Evaluation Of Early Versus Delayed Initiation Of Simvastatin In Patients Who Receive Guideline Based Treatment For Acute Coronary Syndrome
847. ELITE → Evaluation Of Losartan In The Elderly
848. ENCORE I → Evaluation Of Nifedipine And Cerivastatin On Recovery Of Coronary Endothelial Function
849. EPISTENT → Evaluation Of Platelet IIb/IIia Inhibitor For Stenting Trial
850. EPILOG → Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade
851. ERASER → Evaluation Of Reopro And Stenting To Eliminate Restenosis
852. ESCAMI → Evaluation Of The Safety And Cardioprotective Effects Of Eniporide In Acute Myocardial Infarction
853. ETHECC → Evaluation Of Thymitaq In Hepatocellular Carcinoma
854. EVIDENCE → Evidence For Interferon Dose-Effect: European-North American Comparative Efficacy Study (Rebif V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms))
855. Biological evolution → Evolution
856. Evolved → Evolution
857. Theory of evolution → Evolution
858. Evolutionary → Evolution
859. Darwinian evolution → Evolution
860. Evolve → Evolution
861. Evolutionary theory of sex → Evolution of sex
862. Ewan Cameron (Vitamin C) → Ewan Cameron (physician)
863. MOXCON → Excess Mortality In Chf Patients Treated With Sr Moxonidine Leads To Study Termination: Results Of The Sr Moxonidine For Congestive Heart Failure Trial
864. ERBAC → Excimer Laser, Rotational Atherectomy, Balloon Angioplasty Complications Study
865. ELVD-CHF → Exercise In Left Ventricular Dysfunction And Chronic Heart Failure Trial
866. ETICA → Exercise Training Intervention After Coronary Angioplasty: The Etica Trial
867. Expectation maximization → Expectation-maximization algorithm
868. PEPAF → Experimental Program For Physical Activity Promotion
869. Hyper-Cerebral Electrosis → Exploding head
870. EXCLAIM → Extended Clinical Prophylaxis In Acutely Ill Medical Patients (Lovenox (Enoxaparin) Postmarketing (Phase Iv) Trial)